Despite Slow Launch, Vivus's (VVUS) Qsymia Still Has Blockbuster Potential
Tweet Send to a FriendGet Alerts VVUS Hot Sheet
Price: $14.50 +7.25%
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade VVUS Now!
Vivus (Nasdaq: VVUS) launched its highly anticipated weight loss drug Qsymia in the U.S. in Sept. By most accounts, the launch was a disappointment. Analysts at Needham and Company say the less than stellar launch is related to REMS issues, as management cautioned about FDA concerns, opting for a controlled launch. Despite this, analysts believe the drugs still has blockbuster potential.
"In our opinion, complications during the first few weeks of a launch do not preclude the drug from reaching blockbuster status," said analyst Alan Carr.
"In our view these matters can likely be corrected with additional physician education about the REMS procedures as well as expansion from mail-order to retail distribution, which we expect to occur in 2013," said Carr.
Accordingly, Carr feels Vivus stock is undervalued.
Needham & Company reiterated a Buy rating on Vivus with a price target of $20.00.
For an analyst ratings summary and ratings history on Vivus (Nasdaq: VVUS) click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $13.01 yesterday, with a 52 week range of $9.76-$31.21.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"In our opinion, complications during the first few weeks of a launch do not preclude the drug from reaching blockbuster status," said analyst Alan Carr.
"In our view these matters can likely be corrected with additional physician education about the REMS procedures as well as expansion from mail-order to retail distribution, which we expect to occur in 2013," said Carr.
Accordingly, Carr feels Vivus stock is undervalued.
Needham & Company reiterated a Buy rating on Vivus with a price target of $20.00.
For an analyst ratings summary and ratings history on Vivus (Nasdaq: VVUS) click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $13.01 yesterday, with a 52 week range of $9.76-$31.21.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold
- Topeka Capital Starts CEVA Inc. (CEVA) at Buy
- Topeka Capital Starts Cavium Networks (CAVM) at Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
